Heart failure & cardiomyopathies
Finerenone, Glycaemic Status, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial
Authors' conclusion
In patients with HF with mildly reduced/preserved ejection fraction, the beneficial effects of finerenone, compared with placebo, on clinical events and symptoms, were consistent, irrespective of glycaemic status at baseline.
Study context
- Population
- Heart failure (HF) with NYHA II–IV, LVEF ≥40%, structural heart disease and elevated NT-proBNP; subgroups by glycaemic status (normoglycaemia, pre-diabetes, diabetes)
- Participants
- 6,001 participants
- Comparison
- Finerenone vs placebo, by glycaemic status
- Primary endpoint
- CV death and total worsening HF events
Methodological detailsprespecified analysis
- Prespecified analysis
Primary result
As reported in the abstract
Finerenone vs PlaceboRelative risk (95% CI)
Normoglycaemia
0.85(0.63–1.14)
Pre-diabetes
0.85(0.66–1.08)
Diabetes
0.82(0.69–0.98)
Further findings
Glycaemic status at baseline
| Outcome | Adjusted RR (95% CI) | |
|---|---|---|
| Primary endpoint rate by glycaemic status (vs normoglycaemia)Pre-diabetesvs Normoglycaemia | 1.02 (0.84–1.23) | |
| Primary endpoint rate by glycaemic status (vs normoglycaemia)Diabetesvs Normoglycaemia | 1.32 (1.11–1.58) | |
| 0.512Adjusted relative risk (log scale) |
Components of primary outcome, all-cause death, composite kidney endpoints, KCCQ total symptom score improvement
- Effects of finerenone not modified by glycaemic status
Original publication
Finerenone, Glycaemic Status, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Eur J Heart Fail. Published 10 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →